DPP4 and Hypoglycemia: From previous investigations, a therapeutic dosage of different authorized DPP-IV inhibitors led to a two- to threefold raise in endogenous GLP-1 concentration without any inherent hypoglycemia risk and a favorable safety profile (Figure 2).